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SIBO is defined as an overgrowth of bacterial 
flora inhabiting the small intestine and is usually 
described in association with irritable bowel syn‑
drome.5 A number of studies reported the devel‑
opment of SIBO in patients who had undergone 
surgical treatment of gastrointestinal tumors[6] 
or other abnormalities in the gastrointestinal 
tract.7,8 In their paper, Adamska et al4 claimed 
that there had been no studies on the occurrence 
of SIBO in the course of diabetes, including type 
1 diabetes. Indeed, there are few such studies, 
but isolated reports concerning type 1 and 2 di‑
abetes are available. For example, Rana et al9 ex‑
amined patients with type 2 diabetes and dem‑
onstrated a significant increase in the incidence 
of SIBO compared with the healthy population. 
Ojetti et al10 demonstrated that SIBO is present 
much more often in patients with type 1 diabe‑
tes who also have autonomic neuropathy, which 
is associated with a higher daily supply of insu‑
lin. Faria et al11 proved that intestinal transit can 
be inhibited in the course of type 1 diabetes, but 
the incidence of SIBO in this patient group is not 
significantly higher. This study was also cited by 
Adamska et al.4 It is therefore clear that the prob‑
lem is not completely new, but it has not been 
well documented.
In their study, Adamska et al4 employed hydro‑
gen breath testing to diagnose SIBO. The authors 
were right to point out that the gold standard for 
the diagnosis of SIBO is microbiological testing of 
a duodenal or jejunal aspirate; however, it is an in‑
vasive method.4 Breath testing enables a quick and 
noninvasive diagnosis of SIBO, but false results 
are possible (sensitivity of the test when lactu‑
lose is applied is 52%, and specificity—86%).12 
Increased intestinal transit can reduce the sen‑
sitivity of the breath test, which causes a rapid 
removal of lactulose from the proximal small in‑
testine. On the other hand, advanced lung dis‑
eases, such as tumors or inflammations, can re‑
sult in false positive results due to the presence 
of abundant bacterial flora in the lungs.12 It seems 
In recent years, our understanding of the func‑
tion of the human gastrointestinal tract has vast‑
ly improved, especially as regards the role of gas‑
trointestinal microbiota (commensal intestinal 
flora). There is growing evidence for the signifi‑
cant effect of these microbes on the function and 
health of the human body. Commensal flora of 
the gastrointestinal tract plays a vital role in di‑
gestion and absorption of nutrients and protects 
against the invasion of pathogenic microorgan‑
isms by creating resistance to colonization and af‑
fecting the immune system of the host organism. 
The gastrointestinal tract, especially in its final 
section, contains an enormous number of bacte‑
ria, which form a peculiar ecosystem. Gastroin‑
testinal flora is an important part of the body. Its 
role and significance are increasingly recognized, 
which helps explain the course and causes of nu‑
merous diseases. An increasing number of stud‑
ies have reported changes in microbiota compo‑
sition in the course of various diseases, such as 
inflammatory bowel disease,1 celiac disease,2 di‑
abetes, obesity,3 and many others.
Following this trend, Adamska et al,4 in the cur‑
rent issue of the Polish Archives of Internal Medicine 
(Pol Arch Med Wewn), presented the results of their 
studies on small intestinal bacterial overgrowth 
(SIBO) in patients with type 1 diabetes mellitus. 
The study included 148 adults with type 1 diabetes 
mellitus and 41 controls. SIBO was confirmed us‑
ing a noninvasive hydrogen breath test performed 
with Gastro+Gastrolyzer (Bedfont Scientific Ltd., 
Maidstone, United Kingdom). The test consisted 
in assessing the concentration of exhaled hydro‑
gen derived from 20 grams of lactulose admin‑
istered orally and later decomposed by bacteria. 
The incidence of SIBO was shown to be significant‑
ly higher in the control group in comparison with 
the study group (73% and 37.8%, respectively, P = 
0.006), which probably came as surprise to the au‑
thors.4 Similarly, no significant correlations were 
demonstrated between the symptoms of SIBO 
and a positive result of the hydrogen breath test.
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that a similar misrepresentation of the breath test 
results may be caused by advanced tooth decay. 
Clinical symptoms of SIBO are associated with 
bacterial overgrowth in the small intestine. Thus, 
antibiotic therapy is administered (eg, using ri‑
faximin), which should reduce the number of bac‑
terial cells and thus remove or alleviate symp‑
toms. That is why, the use of antibiotic therapy 
should verify the results of the breath test.6 Long 
et al13 conducted a study with the use of breath 
testing and antibiotic therapy and demonstrat‑
ed that the results did not coincide with a clinical 
improvement after the administration of rifaxi‑
min. For this reason, they questioned the signif‑
icance of the breath test. It is a pity that the au‑
thors4 did not expand the study protocol to in‑
clude the use of rifaximin or other antibiotic in 
patients in whom the breath test gave a posi‑
tive result. Following antibiotic therapy, the test 
might have been repeated and the results juxta‑
posed with the patients’ clinical state. Such an ap‑
proach would have enhanced the value of the re‑
search. Surely, an invasive study involving the use 
of a duodenal aspirate and microbiological testing 
would be the best solution in this case, but it was 
not performed due to obvious reasons.
Adamska et al4 decided to apply a noninva‑
sive method for diagnosing SIBO in patients with 
type 1 diabetes mellitus, which should be val‑
ued considering the scarce number of similar at‑
tempts. Our doubts concerning the applied meth‑
od are not supposed to undermine  the results of 
the analysis but rather to encourage the authors 
to conduct further research, which we hope they 
will undertake. It seems clear that the research on 
the impact of commensal microflora on the hu‑
man body will continue to develop rapidly.
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